专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180326042A1 DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING DRIED INFLUENZA VACCINE PREPARATION 审中-公开
公开(公告)号：US20180326042A1
公开(公告)日：2018-11-15
申请号：US15777441
申请日：2016-11-28
申请人： NITTO DENKO CORPORATION
发明人： Eiji KIYOTOH , Mitsuhiko HORI , Daisuke ASARI , Katsuyuki OKUBO , Takuya SHISHIDO , Masahiro FUKASAKA , Kyohei MATSUSHITA
IPC分类号： A61K39/145 , A61K9/19 , A61K47/18 , A61K47/26
CPC分类号： A61K39/145 , A61K9/19 , A61K39/00 , A61K47/18 , A61K47/183 , A61K47/26 , A61K2039/5252 , A61K2039/55511 , A61P31/16
摘要： The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an-amino acid.

2. 发明申请

US20180147235A1 ALLERGY VACCINE COMPOSITION 审中-公开
公开(公告)号：US20180147235A1
公开(公告)日：2018-05-31
申请号：US15570851
申请日：2016-04-28
申请人： NITTO DENKO CORPORATION
发明人： Kyohei MATSUSHITA , Masahiro FUKASAKA , Takuya SHISHIDO , Daisuke ASARI , Katsuyuki OKUBO , Mitsuhiko HORI
IPC分类号： A61K31/739 , A61K39/35 , A61K39/02 , A61P17/04 , A61P37/02 , A61P37/08 , A61P11/06 , A61P11/02
摘要： The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease. The vaccine composition contains: an immunomodulator which is a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt of the lipopolysaccharide; and at least one allergen.

3. 发明申请

US20160193327A1 MUCOSAL VACCINE COMPOSITION 审中-公开
标题翻译：胶原蛋白组合物
公开(公告)号：US20160193327A1
公开(公告)日：2016-07-07
申请号：US14917084
申请日：2014-10-02
申请人： NITTO DENKO CORPORATION
发明人： Masahiro FUKASAKA , Mitsuhiko HORI , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Eiji KIYOTOH , Kyohei MATSUSHITA
IPC分类号： A61K39/385 , A61K39/09 , A61K39/12 , A61K39/15 , A61K39/29 , A61K39/165 , A61K39/155 , A61K39/20 , A61K39/08 , A61K39/25 , A61K39/04 , A61K39/205 , A61K39/13 , C12N7/00 , A61K47/48 , A61K39/145
CPC分类号： A61K39/385 , A61K9/006 , A61K39/04 , A61K39/08 , A61K39/092 , A61K39/12 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/155 , A61K39/165 , A61K39/20 , A61K39/205 , A61K39/25 , A61K39/29 , A61K39/292 , A61K2039/541 , A61K2039/55572 , A61K2039/575 , C12N7/00 , C12N2710/16734 , C12N2710/20034 , C12N2720/12334 , C12N2730/10134 , C12N2760/16034 , C12N2760/16134 , C12N2760/16234 , C12N2760/18434 , C12N2760/18734 , C12N2760/20134 , C12N2770/24134 , C12N2770/32434 , C12N2770/32634 , C12N2770/36234
摘要： The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
摘要翻译：本发明的目的是提供一种粘膜疫苗组合物，其可以施用于口内粘膜，眼粘膜，耳粘膜，生殖器粘膜，咽粘膜，呼吸道粘膜，支气管粘膜，肺粘膜，胃粘膜，肠粘膜或直肠粘膜，其可用作感染性疾病或癌症的预防或治疗剂，并且能够安全有效地诱导全身免疫应答和粘膜免疫应答。本发明提供一种粘膜疫苗组合物，其用于至少一种选自人或动物口腔内粘膜，眼粘膜，耳粘膜，生殖器粘膜，咽粘膜，呼吸道粘液的粘膜膜，支气管粘膜，肺粘膜，胃粘膜，肠粘膜和直肠粘膜，含有至少一种抗原; 并且作为佐剂，衍生自选自沙雷氏菌属（Salratia），莱克氏菌属（Leclercia），R，属（Rahnella），酸性d螨属（Acidicaldus），酸性，螨属（Acidical il ium，，，era era era era era era era，，，，，，，，Acid Acid Acid Acid as as，As As As ia ia ia ia ia C occus occus occus occus occus，，，ia ia，，，，，，，，，，，（Leahibacter），红球菌属（Myocosococcus），梭状芽孢杆菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，蓝假丝酵母属，蓝假丝酵母属，蓝假丝酵母属，和肠杆菌属或其盐。

4. 发明申请

US20200376111A1 VACCINE COMPOSITION 审中-公开
公开(公告)号：US20200376111A1
公开(公告)日：2020-12-03
申请号：US16996433
申请日：2020-08-18
申请人： NITTO DENKO CORPORATION
发明人： Masahiro FUKASAKA , Arimichi OKAZAKI , Daisuke ASARI , Mitsuhiko HORI , Shizuo AKIRA , Osamu TAKEUCHI
IPC分类号： A61K39/145 , A61K39/12 , A61K39/39 , C12N7/00
摘要： A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

5. 发明申请

US20160287697A1 INJECTABLE VACCINE COMPOSITION 有权
标题翻译：可注射的疫苗组合物
公开(公告)号：US20160287697A1
公开(公告)日：2016-10-06
申请号：US14916807
申请日：2014-10-02
申请人： NITTO DENKO CORPORATION
发明人： Kyohei MATSUSHITA , Masahiro FUKASAKA , Arimichi OKAZAKI , Eiji KIYOTOH , Katsuyuki OKUBO , Daisuke ASARI , Mitsuhiko HORI
IPC分类号： A61K39/39 , A61K9/00
CPC分类号： A61K39/39 , A61K9/0019 , A61K39/00 , A61K2039/55572
摘要： The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
摘要翻译：本发明的目的在于提供一种安全有效的可用作癌症或感染性疾病的预防或治疗剂并且能够安全有效地诱导全身免疫应答的可注射疫苗组合物。本发明是通过注射给人或动物施用的可注射疫苗组合物，其包含至少一种抗原和佐剂，衍生自至少一种革兰氏阴性细菌的脂多糖，所述至少一种阴性细菌选自沙雷氏菌属，Leclercia，Rahnella，Acidicaldus，Acidiphilium，Acidisphaera，Acidocella，Acidomonas，Asaia，Belnapia，Craurococcus，Gluconacetobacter，Gluconobacter，Kozakia，Leahibacter，Muricoccus，Neoasaia，Oleomonas，Paracraurococcus，Rhodopila，Roseococcus，Rubritepida，Saccharibacter，Stella，Swaminathania，Teichococcus ，Zavarzinia，假单胞菌属，无色杆菌属，芽孢杆菌属，甲烷球菌属，甲烷球菌属，梭菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，肠杆菌属或其盐。

6. 发明申请

US20180326041A1 VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR MANUFACTURING VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION 审中-公开
公开(公告)号：US20180326041A1
公开(公告)日：2018-11-15
申请号：US15777396
申请日：2016-11-28
申请人： NITTO DENKO CORPORATION
发明人： Takuya SHISHIDO , Daisuke ASARI , Eiji KIYOTOH , Kyohei MATSUSHITA , Wenjing LI , Masahiro FUKASAKA , Katsuyuki OKUBO , Mitsuhiko HORI
IPC分类号： A61K39/145 , A61K9/19 , A61K47/18 , A61K47/26 , A61K47/38 , A61K47/36
CPC分类号： A61K39/145 , A61K9/19 , A61K47/183 , A61K47/26 , A61K47/36 , A61K47/38 , A61K2039/5252 , A61K2039/542 , A61K2039/55511 , A61K2039/70 , A61P31/16
摘要： The present invention provides a vaccine pharmaceutical composition for oral administration that enables stable storage of an influenza virus antigen and a method for producing the pharmaceutical composition. Provided is a vaccine pharmaceutical composition for oral administration containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.

7. 发明申请

US20170028054A1 VACCINE COMPOSITION 审中-公开
标题翻译：疫苗组合物
公开(公告)号：US20170028054A1
公开(公告)日：2017-02-02
申请号：US15290031
申请日：2016-10-11
申请人： NITTO DENKO CORPORATION
发明人： Masahiro FUKASAKA , Arimichi OKAZAKI , Daisuke ASARI , Mitsuhiko HORI , Shizuo AKIRA , Osamu TAKEUCHI
IPC分类号： A61K39/145 , C12N7/00 , A61K39/39
CPC分类号： A61K39/145 , A61K39/12 , A61K39/39 , A61K2039/5252 , A61K2039/541 , A61K2039/542 , A61K2039/55561 , A61K2039/55572 , A61K2039/575 , C12N7/00 , C12N2710/00034 , C12N2760/16034 , C12N2760/16134 , Y02A50/386 , Y02A50/41 , Y02A50/412 , Y02A50/489
摘要： An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
摘要翻译：提供可用于感染性疾病的预防或治疗剂，有效诱导全身免疫应答或粘膜免疫应答的口服给药的疫苗组合物。一种用于给予人或动物口腔的疫苗组合物，所述疫苗组合物含有至少一种源自感染性疾病的抗原，以及至少一种选自toll样受体4（TLR4）激动剂，一种toll样受体2/6（TLR2 / 6）激动剂和环二核苷酸，或其衍生物或盐。

8. 发明申请

US20160206728A1 DRIED INFLUENZA VACCINE PREPARATION AND METHOD OF PRODUCING THE SAME 审中-公开
标题翻译：干燥的流感疫苗制剂及其制备方法
公开(公告)号：US20160206728A1
公开(公告)日：2016-07-21
申请号：US14915342
申请日：2014-10-02
申请人： NITTO DENKO CORPORATION
发明人： Eiji KIYOTOH , Mitsuhiko HORI , Daisuke ASARI , Arimichi OKAZAKI , Masahiro FUKASAKA
IPC分类号： A61K39/145 , C12N7/00
CPC分类号： A61K39/145 , A61K9/19 , A61K31/7016 , A61K39/12 , A61K47/26 , A61K2039/525 , A61K2039/55511 , C12N7/00 , C12N2760/16034 , C12N2760/16134 , A61K2300/00
摘要： The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation. The present invention provides a dried influenza vaccine preparation containing an influenza vaccine antigen and a disaccharide, wherein the disaccharide is at least one selected from the group consisting of sucrose, maltose, palatinose, melibiose, isomalt, cellobiose, allolactose, isomaltose, sophorose, lactobionic acid, laminaribiose, xylobiose, turanose, gentiobiose, rutinose, kojibiose, nigerose, robinose, neohesperidose, sucralose, and maltitol.
摘要翻译：本发明提供一种干流感疫苗制剂，其中流感疫苗抗原的活性即使在不严格保持低温储存的情况下也可以稳定地保持，并且可以稳定地供应。本发明还提供了制备干流感疫苗制剂的方法。本发明提供含有流感疫苗抗原和二糖的干燥流感疫苗制剂，其中二糖是选自蔗糖，麦芽糖，帕拉金糖，蜜二糖，异麦芽糖醇，纤维二糖，异乳糖，异麦芽糖，槐糖，乳糖酸酸，层状二糖，木二糖，吐木糖，龙胆糖，芦丁糖，曲霉糖，尼黑糖，罗西糖，新月皮糖，三氯蔗糖和麦芽糖醇。

9. 发明申请

US20160228540A1 NASAL MUCOSAL VACCINE COMPOSITION 审中-公开
标题翻译： NASAL MUCOSAL VACCINE组合物
公开(公告)号：US20160228540A1
公开(公告)日：2016-08-11
申请号：US14916721
申请日：2014-10-02
申请人： NITTO DENKO CORPORATION
发明人： Eiji KIYOTOH , Mitsuhiko HORI , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Masahiro FUKASAKA , Kyohei MATSUSHITA
IPC分类号： A61K39/39 , A61K39/09 , A61K39/12 , A61K39/15 , A61K39/145 , A61K39/125 , A61K39/165 , A61K39/08 , A61K39/25 , A61K39/205 , A61K39/00 , A61K39/13
CPC分类号： A61K39/39 , A61K39/00 , A61K39/0011 , A61K39/08 , A61K39/092 , A61K39/12 , A61K39/125 , A61K39/13 , A61K39/145 , A61K39/15 , A61K39/165 , A61K39/205 , A61K39/25 , A61K2039/5252 , A61K2039/5254 , A61K2039/543 , A61K2039/55572 , A61K2039/575 , C12N2710/16734 , C12N2710/20034 , C12N2720/12334 , C12N2760/18434 , C12N2760/18734 , C12N2760/20134 , C12N2770/24134 , C12N2770/32434 , C12N2770/32634 , C12N2770/36234
摘要： The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
摘要翻译：本发明提供一种鼻粘膜疫苗组合物，其是安全的，可用作感染性疾病或癌症的预防或治疗剂，并且能够有效地诱导全身免疫应答和粘膜免疫应答。本发明提供了向人或动物鼻粘膜施用的鼻粘膜疫苗组合物，所述鼻粘膜疫苗组合物含有至少一种除了源自流感病毒的抗原之外的抗原; 并且作为佐剂，衍生自选自沙雷氏菌属（Salratia），莱克氏菌属（Leclercia），R，属（Rahnella），酸性d螨属（Acidicaldus），酸性，螨属（Acidical il ium，，，era era era era era era era，，，，，，，，Acid Acid Acid Acid as as，As As As ia ia ia ia ia C occus occus occus occus occus，，，ia ia，，，，，，，，，，，（Leahibacter），红球菌属（Myocosococcus），梭状芽孢杆菌属，微球菌属，黄杆菌属，泛菌属，醋杆菌属，发酵单胞菌属，黄单胞菌属，蓝假丝酵母属，蓝假丝酵母属，蓝假丝酵母属，和肠杆菌属或其盐。

10. 发明申请

US20160213773A1 MUCOSAL VACCINE COMPOSITION 审中-公开
公开(公告)号：US20160213773A1
公开(公告)日：2016-07-28
申请号：US14917077
申请日：2014-10-02
申请人： NITTO DENKO CORPORATION
发明人： Masahiro FUKASAKA , Mitsuhiko HORI , Katsuyuki OKUBO , Daisuke ASARI , Arimichi OKAZAKI , Eiji KIYOTOH , Kyohei MATSUSHITA
IPC分类号： A61K39/39 , A61K39/09 , C12N7/00 , A61K39/15 , A61K39/13 , A61K39/00 , A61K39/145 , A61K39/12
CPC分类号： A61K39/39 , A61K39/00 , A61K39/0005 , A61K39/092 , A61K39/12 , A61K39/13 , A61K39/145 , A61K39/15 , A61K2039/52 , A61K2039/525 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/544 , A61K2039/55572 , C12N7/00 , C12N2710/20034 , C12N2720/12334 , C12N2760/16034 , C12N2770/32634
摘要： The present invention aims at providing a vaccine composition capable of being administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the mucosal vaccine composition containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof, wherein a mass ratio between the adjuvant and the antigen (total mass of the adjuvant/total mass of the antigen) is 0.002 to 500.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式